were within normal limits and a skeletal survey showed no lytic lesions. Using nephelometry, IgG levels were 2,340 mg/dl (normal range, 751-1,560 mg/dl) and λ light chains levels were 2,450 mg/dl (normal range, 313-723 mg/dl), without depression of the other immunoglobulins. One month later, examination of a new bone marrow smear revealed that mature plasma cells rose to 45%, while a bone marrow aspirate disclosed diffuse bone marrow infiltration by plasma cells that were shown to be λ light chain positive with immunoperoxidase staining. The patient was treated with melphalan (Alkeran ® ; GlaxoSmithKline, Philadelphia, http://www.gsk.com) and prednisone (Deltasone ® ; Pfizer Pharmaceuticals, New York, http://www.pfizer.com); imatinib was continued. Eight months later, a bone marrow aspirate showed normal findings (plasma cells 1.5%) and so did nephelometry.
The chromosomal abnormality detected in our patient is a complex Ph 1 chromosome containing translocations between chromosomes 9, 14, and 22 and involves the locus of the λ light chain (22q11). This abnormality might have triggered the development of the two distinct hematologic malignancies: CML and IgGλ MM.
Our patient developed MM after 7 months of treatment with imatinib mesylate. Whether the development of MM was spontaneous or accelerated by imatinib is difficult to prove. Recently, imatinib has been shown to inhibit proliferation of MM cells in vitro by arresting cell-cycle The Oncologist ® Letter to the Editor
